Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03277313 Completed - Clinical trials for Primary Immunodeficiency Diseases (PID)

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Start date: September 25, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to <16 years) participants with primary immunodeficiency disease (PIDD).

NCT ID: NCT03277261 Completed - Clinical trials for Relapsing Multiple Sclerosis (RMS)

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

ULTIMATE 1
Start date: September 19, 2017
Phase: Phase 3
Study type: Interventional

This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.

NCT ID: NCT03277248 Completed - Clinical trials for Relapsing Multiple Sclerosis (RMS)

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

ULTIMATE II
Start date: August 25, 2017
Phase: Phase 3
Study type: Interventional

This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.

NCT ID: NCT03276897 Completed - Clinical trials for Face Aging/Photo Aging of Moderate Grade

Efficacy and Tolerance Evaluation of a "Revitalizing" Face Treatment

Start date: March 21, 2017
Phase: N/A
Study type: Interventional

Efficacy and Tolerance Evaluation of a"revitalizing" face treatment consisting of a day and a night cream

NCT ID: NCT03276637 Completed - Healthy Adults Clinical Trials

Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force

MilSeq
Start date: August 23, 2017
Phase: N/A
Study type: Interventional

The MilSeq Project is a nonrandomized, prospective pilot study of whole exome sequencing (WES) in the U.S. Air Force. The purpose of this study is to explore the implementation of WES into clinical medical care in the military health system.

NCT ID: NCT03276468 Completed - Follicular Lymphoma Clinical Trials

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts: - relapsed/refractory follicular lymphoma (FL) patients - relapsed/refractory aggressive (DLBCL) lymphoma patients - relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)

NCT ID: NCT03276325 Completed - Clinical trials for Lower Abdominal Oncologic Surgery

Epidural Steroids With Intrathecal Nalbuphine for Lower Abdominal Oncologic Surgery

Start date: September 15, 2017
Phase: N/A
Study type: Interventional

Intraoperative pain, nausea, vomiting, hypotension, bradycardia are known side effects during lower abdominal surgery under spinal anesthesia, Time to 2 segment regression of sensory block and duration of effective analgesia prolonged with intrathecal (IT) 0.4 mg nalbuphine & IT 0.8 mg nalbuphine, but the incidence of side-effects was significantly higher with IT 0.8 mg nalbuphine compared with (IT) 0.4 mg nalbuphine.

NCT ID: NCT03276078 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Start date: November 23, 2017
Phase: Phase 2
Study type: Interventional

A Phase IIa, open-label, repeat-dose trial to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide/Formoterol Fumarate 400/12 μg in 20 Chinese male and female patients with stable moderate to severe COPD.

NCT ID: NCT03276039 Completed - Clinical trials for Non Alcoholic Fatty Liver Disease

Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus

Start date: April 15, 2014
Phase: N/A
Study type: Observational

This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ultrasound was done to patients and controls. Plasma pentraxin-3 (PTX3) was measured using ELISA. Comparison between three groups was done regarding plasma pentraxin-3. Higher levels of plasma PTX3 were detected in NAFLD patients irrespective of presence or absence of chronic HCV infection. Plasma PTX3 could be used as a non-invasive test for prediction of metabolic syndrome in the high-risk population with high sensitivity and moderate specificity.

NCT ID: NCT03275948 Completed - Clinical trials for Metabolic Disorders and Cognitive Decline

Effects of Whole Grain Rye on Metabolic Risk Markers and Mood

Start date: November 1, 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate, in healthy middle age subjects, effects of whole grain rye on cognitive functions, mood, and cardiovasculair risk markers